Filing Details
- Accession Number:
- 0001140361-17-041378
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-11-07 16:07:08
- Reporting Period:
- 2017-11-03
- Accepted Time:
- 2017-11-07 16:07:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1367644 | Emergent Biosolutions Inc. | EBS | Pharmaceutical Preparations (2834) | 141902018 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1380187 | Daniel Abdun-Nabi | 400 Professional Dr, Suite 400 Gaithersburg MD 20879 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-11-03 | 11,508 | $22.03 | 215,642 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-11-03 | 11,508 | $42.50 | 204,134 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2017-11-03 | 20,000 | $14.44 | 224,134 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-11-03 | 20,000 | $42.92 | 204,134 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-11-03 | 11,508 | $0.00 | 11,508 | $22.03 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-11-03 | 20,000 | $0.00 | 20,000 | $14.44 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-03-14 | No | 4 | M | Direct | |
| 41,906 | 2019-03-12 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,000 | Indirect | By Son |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.47 to $42.78, inclusive.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.70 to $43.00, inclusive.
- The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- Consists of an option granted under the company's stock incentive plan as amended and restated.
- The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.
Billionaire Hedge Funds
